Skip header and navigation

Refine By

2021 records – page 1 of 203.

5-alpha-reductase 2 polymorphisms as risk factors in prostate cancer.

https://arctichealth.org/en/permalink/ahliterature19112
Source
Pharmacogenetics. 2002 Jun;12(4):307-12
Publication Type
Article
Date
Jun-2002
Author
Söderström T
Wadelius M
Andersson S-O
Johansson J-E
Johansson S
Granath F
Rane A
Author Affiliation
Department of Medical Sciences, Clinical Pharmacology, University Hospital, S-751 85 Uppsala, Sweden. torbjorn.soderstrom@lmk.ck.lul.se
Source
Pharmacogenetics. 2002 Jun;12(4):307-12
Date
Jun-2002
Language
English
Publication Type
Article
Keywords
Age Factors
Aged
Alleles
Case-Control Studies
Cell Differentiation
DNA - blood - metabolism
DNA Primers - chemistry
European Continental Ancestry Group
Genotype
Heterozygote
Humans
Male
Middle Aged
Neoplasm Staging
Odds Ratio
Polymerase Chain Reaction
Polymorphism, Genetic
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms - enzymology - etiology - genetics
Research Support, Non-U.S. Gov't
Risk factors
Sweden - epidemiology
Testosterone 5-alpha-Reductase - genetics
Abstract
Prostate cancer is a significant cause of death in Western countries and is under the strong influence of androgens. The steroid 5alpha-reductase 2 catalyzes the metabolism of testosterone into the more potent androgen dihydrotestosterone in the prostate gland. The enzyme is a target in pharmacological treatment of benign prostatic hyperplasia using specific inhibitors such as finasteride. Makridakis et al. have characterized the V89L and A49T polymorphisms in recombinant expression systems. The L allelic variant has a lower Vmax/Km ratio than the V variant. In the A49T polymorphism, the T variant has an increased Vmax/Km ratio. We performed a population-based case-control study of the impact of the SRD5A2 V89L and A49T polymorphisms on the risk of prostate cancer. We also studied the relation between the genotypes and age at diagnosis, tumor, node, metastasis stage, differentiation grade, prostate specific antigen and heredity. The study included 175 prostate cancer patients and 159 healthy controls that were matched for age. There was an association with SRD5A2 V89L LL genotype and metastases at the time of diagnosis, OR 5.67 (95% CI 1.44-22.30) when adjusted for age, differentiation grade, T-stage and prostate specific antigen. Heterozygous prostate cancer cases that carried the SRD5A2 A49T AT genotype were significantly younger than cases that carried the AA genotype, (mean age 66 years vs 71, P = 0.038). The SRD5A2 V89L and A49T polymorphisms were, however, not associated with altered prostate cancer risk. Further studies of the V89L polymorphism may lead to better understanding of the etiology of prostate cancer metastases.
PubMed ID
12042668 View in PubMed
Less detail

8-Hydroxydeoxyguanosine: a new potential independent prognostic factor in breast cancer.

https://arctichealth.org/en/permalink/ahliterature97933
Source
Br J Cancer. 2010 Mar 16;102(6):1018-23
Publication Type
Article
Date
Mar-16-2010
Author
H. Sova
A. Jukkola-Vuorinen
U. Puistola
S. Kauppila
P. Karihtala
Author Affiliation
Department of Oncology and Radiotherapy, Oulu University Hospital, Finland. henrijuh@mail.student.oulu.fi
Source
Br J Cancer. 2010 Mar 16;102(6):1018-23
Date
Mar-16-2010
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Breast Neoplasms - diagnosis - metabolism - mortality - pathology
Carcinoma, Ductal, Breast - diagnosis - metabolism - mortality - pathology
Deoxyguanosine - analogs & derivatives - blood - metabolism
Female
Humans
Immunohistochemistry
Middle Aged
Neoplasm Staging
Prognosis
Survival Analysis
Tumor Markers, Biological - analysis - metabolism
Abstract
BACKGROUND: 8-Hydroxydeoxyguanosine (8-oxodG) is the commonly used marker of oxidative stress-derived DNA damage. 8-OxodG formation is regulated by local antioxidant capacity and DNA repair enzyme activity. Earlier studies have reported contradictory data on the function of 8-oxodG as a prognostic factor in different cancer types. METHODS: We assessed pre-operative serum 8-oxodG levels with an enzyme-linked immunosorbent assay in a well-defined series of 173 breast cancer patients. 8-OxodG expression in the nuclei of cancer cells from 150 of these patients was examined by immunohistochemistry. RESULTS: The serum 8-oxodG levels and immunohistochemical 8-oxodG expression were in concordance with each other (P
PubMed ID
20179711 View in PubMed
Less detail

10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients.

https://arctichealth.org/en/permalink/ahliterature141809
Source
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1323-9
Publication Type
Article
Date
Aug-1-2011
Author
Juanita Crook
Jette Borg
Andrew Evans
Ants Toi
E P Saibishkumar
Sharon Fung
Clement Ma
Author Affiliation
Department of Radiation Oncology, Princess Margaret Hospital, Toronto, Ontario, Canada. jcrook@bccancer.bc.ca
Source
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1323-9
Date
Aug-1-2011
Language
English
Publication Type
Article
Keywords
Adenocarcinoma - blood - mortality - pathology - radiotherapy
Aged
Aged, 80 and over
Brachytherapy - adverse effects - methods
Disease-Free Survival
Humans
Iodine Radioisotopes - therapeutic use
Male
Middle Aged
Neoadjuvant Therapy - methods
Neoplasm Staging
Ontario
Penile Erection - physiology
Proportional Hazards Models
Prospective Studies
Prostate
Prostate-Specific Antigen - blood
Prostatic Neoplasms - blood - mortality - pathology - radiotherapy
Radiotherapy Dosage
Urination Disorders - drug therapy
Abstract
To report outcomes for 1,111 men treated with iodine-125 brachytherapy (BT) at a single institution.
A total of 1,111 men (median age, 63) were treated with iodine-125 prostate BT for low- or intermediate-risk prostate cancer between March 1999 and November 2008. Median prostate-specific antigen (PSA) level was 5.4 ng/ml (range, 0.9-26.1). T stage was T1c in 66% and T2 in 34% of patients. Gleason score was 6 in 90.1% and 7 or 8 in 9.9% of patients. Neoadjuvant hormonal therapy (2-6 months course) was used in 10.1% of patients and combined external radiotherapy (45 Gy) with BT (110 Gy) in 4.1% (n = 46) of patients. Univariate and multivariate Cox proportional hazards were used to determine predictors of failure.
Median follow-up was 42 months (range, 6-114), but for biochemical freedom from relapse, a minimum PSA test follow-up of 30 months was required (median 54; n = 776). There were 27 failures, yielding an actuarial 7-year disease-free survival rate of 95.2% (96 at risk beyond 84 months). All failures underwent repeat 12-core transrectal ultrasound -guided biopsies, confirming 8 local failures. On multivariate analysis, Gleason score was the only independent predictor of failure (p = 0.001; hazard ratio, 4.8 (1.9-12.4). Median International Prostate Symptom score from 12 to 108 months ranged between 3 and 9. Of the men reporting baseline potency, 82.8% retained satisfactory erectile function beyond 5 years.
Iodine-125 prostate BT is a highly effective treatment option for favorable- and intermediate-risk prostate cancer and is associated with maintenance of good urinary and erectile functions.
PubMed ID
20675072 View in PubMed
Less detail

10-year survival and quality of life in patients with high-risk pN0 prostate cancer following definitive radiotherapy.

https://arctichealth.org/en/permalink/ahliterature94068
Source
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1074-83
Publication Type
Article
Date
Nov-15-2007
Author
Berg Arne
Lilleby Wolfgang
Bruland Oyvind Sverre
Fosså Sophie Dorothea
Author Affiliation
Faculty of Medicine, University of Oslo, Oslo, Norway. arne.berg@radiumhospitalet.no
Source
Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1074-83
Date
Nov-15-2007
Language
English
Publication Type
Article
Keywords
Aged
Aged, 80 and over
Analysis of Variance
Case-Control Studies
Disease Progression
Erectile Dysfunction - physiopathology
Follow-Up Studies
Health status
Health Surveys
Humans
Male
Middle Aged
Neoplasm Staging
Norway
Prostatic Neoplasms - mortality - pathology - radiotherapy
Quality of Life
Radiotherapy, Conformal
Survival Analysis
Urination Disorders - physiopathology
Abstract
PURPOSE: To evaluate long-term overall survival (OS), cancer-specific survival (CSS), clinical progression-free survival (cPFS), and health-related quality of life (HRQoL) following definitive radiotherapy (RT) given to T(1-4p)N(0)M(0) prostate cancer patients provided by a single institution between 1989 and 1996. METHODS AND MATERIALS: We assessed outcome among 203 patients who had completed three-dimensional conformal RT (66 Gy) without hormone treatment and in whom staging by lymphadenectomy had been performed. OS was compared with an age-matched control group from the general population. A cross-sectional, self-report survey of HRQoL was performed among surviving patients. RESULTS: Median observation time was 10 years (range, 1-16 years). Eighty-one percent had high-risk tumors defined as T(3-4) or Gleason score (GS) > or =7B (4+3). Among these, 10-year OS, CSS, and cPFS rates were 52%, 66%, and 39%, respectively. The corresponding fractions in low-risk patients (T(1-2) and GS or =7B.
PubMed ID
17703896 View in PubMed
Less detail

17beta-hydroxysteroid dehydrogenase type 1 is an independent prognostic marker in breast cancer.

https://arctichealth.org/en/permalink/ahliterature17431
Source
Cancer Res. 2004 Oct 15;64(20):7604-9
Publication Type
Article
Date
Oct-15-2004
Author
Olayiwola O Oduwole
Yan Li
Veli V Isomaa
Anne Mäntyniemi
Anitta E Pulkka
Ylermi Soini
Pirkko T Vihko
Author Affiliation
Biocenter Oulu and Research Center for Molecular Endocrinology, WHO Collaborating Centre for Research on Reproductive Health, Oulu, Finland.
Source
Cancer Res. 2004 Oct 15;64(20):7604-9
Date
Oct-15-2004
Language
English
Publication Type
Article
Keywords
17-Hydroxysteroid Dehydrogenases - biosynthesis - genetics
Breast Neoplasms - enzymology - genetics - metabolism - pathology
Estrogen Receptor alpha - biosynthesis - genetics
Estrogen Receptor beta - biosynthesis - genetics
Female
Humans
Immunohistochemistry
In Situ Hybridization
Isoenzymes
Ki-67 Antigen - biosynthesis - genetics
Middle Aged
Neoplasm Staging
Paraffin Embedding
Prognosis
RNA, Messenger - biosynthesis - genetics
Receptor, erbB-2 - biosynthesis - genetics
Research Support, Non-U.S. Gov't
Tumor Markers, Biological - biosynthesis - genetics
Abstract
Estrogens have an important role in the development and progression of breast cancer. 17beta-Hydroxysteroid dehydrogenase type 1 (17HSD1), type 2 (17HSD2), and type 5 (17HSD5) are associated with sex steroid metabolism in normal and cancerous breast tissue. The mRNA expressions of the 17HSD1, 17HSD2, and 17HSD5 enzymes were analyzed in 794 breast carcinoma specimens by using tissue microarrays and normal histologic sections. The results were correlated with the estrogen receptor alpha (ER-alpha) and beta (ER-beta), progesterone receptor, Ki67, and c-erbB-2 expressions analyzed by immunohistochemical techniques and with the Tumor-Node-Metastasis classification, tumor grade, disease-free interval, and survival of the patients. Signals for 17HSD1 mRNA were detected in 16%, 17HSD2 in 25%, and 17HSD5 in 65% of the breast cancer specimens. No association between the 17HSD1, 17HSD2, and 17HSD5 expressions was detected. A significant association was observed between ER-alpha and ER-beta (P = 0.02; odds ratio, 1.96) expressions. There was also a significant inverse association between ER-alpha and 17HSD1 (P = 0.04; odds ratio, 0.53), as well as ER-alpha and 17HSD5 (P = 0.001; odds ratio, 0.35). Patients with tumors expressing 17HSD1 mRNA or protein had significantly shorter overall and disease-free survival than the other patients (P = 0.0010 and 0.0134, log rank). The expression of 17HSD5 was significantly higher in breast tumor specimens than in normal tissue (P = 0.033; odds ratio, 5.56). The group with 17HSD5 overexpression had a worse prognosis than the other patients (P = 0.0146). ER-alpha also associated with survival (P = 0.045). Cox multivariate analyses showed that 17HSD1 mRNA, tumor size, and ER-alpha had independent prognostic significance.
PubMed ID
15492288 View in PubMed
Less detail

17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer.

https://arctichealth.org/en/permalink/ahliterature18039
Source
J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):133-40
Publication Type
Article
Date
Nov-2003
Author
Olayiwola O Oduwole
Markus J Mäkinen
Veli V Isomaa
Anitta Pulkka
Petra Jernvall
Tuomo J Karttunen
Pirkko T Vihko
Author Affiliation
Biocenter Oulu, Research Center for Molecular Endocrinology, WHO Collaborating Centre for Research on Reproductive Health, P.O. Box 5000, University of Oulu, FIN-90014 Oulu, Finland.
Source
J Steroid Biochem Mol Biol. 2003 Nov;87(2-3):133-40
Date
Nov-2003
Language
English
Publication Type
Article
Keywords
17-Hydroxysteroid Dehydrogenases - genetics - metabolism
Adult
Aged
Aged, 80 and over
Colonic Neoplasms - enzymology - genetics - pathology
Comparative Study
Estrogens - metabolism
Female
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Humans
Isoenzymes - metabolism
Male
Middle Aged
Neoplasm Staging
Prognosis
Proportional Hazards Models
RNA, Messenger - biosynthesis - genetics
Research Support, Non-U.S. Gov't
Sex Factors
Survival Rate
Abstract
The mRNA expression of 17beta-hydroxysteroid dehydrogenase (17HSD) types 1 and 2 enzymes catalyzing opposite reaction of estrogen metabolism was investigated in colon cancer. Further, the significance of the 17HSD type 2 enzyme as a possible marker of colorectal cancer (CRC) prognosis was studied. In the normal mucosa, 17HSD type 2 mRNA was predominantly expressed in the surface epithelium and in the upper parts of the crypts. In the lamina propria expression was seen in endothelial cells and mononuclear phagocytes. In colorectal tumors, 17HSD type 2 expression was in most cases downregulated. Female patients had significantly more cancers with high 17HSD type 2 mRNA expression (n=11/35; 31%) than male patients (n=3/39; 8%) (P=0.02). We observed a significant impact of 17HSD type 2 mRNA expression on survival in female patients with distal colorectal cancer (n=24), with an overall cumulative 5-year survival rate of 54% in those with low 17HSD type 2 mRNA expression. None of the female patients with high 17HSD type 2 mRNA expression survived (n=11; P=0.0068; log rank 7.32). In male patients, no significant association with survival was observed. Our data provide evidence suggesting that low 17HSD type 2 mRNA expression is an independent marker of favorable prognosis in females with distal colorectal cancer, supporting the presence of gender- and location-related differences in the pathogenesis of colon cancer.
PubMed ID
14672733 View in PubMed
Less detail

(18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study.

https://arctichealth.org/en/permalink/ahliterature276760
Source
BMC Cancer. 2016;16:10
Publication Type
Article
Date
2016
Author
Randi F Fonager
Helle D Zacho
Niels C Langkilde
Lars J Petersen
Source
BMC Cancer. 2016;16:10
Date
2016
Language
English
Publication Type
Article
Keywords
Bone Neoplasms - pathology - radiography
Denmark
Fluorine Radioisotopes - chemistry
Humans
Male
Multimodal Imaging
Neoplasm Metastasis
Neoplasm Staging
Positron-Emission Tomography
Prostatic Neoplasms - pathology - radiography
Risk factors
Tomography, X-Ray Computed
Abstract
For decades, planar bone scintigraphy has been the standard practice for detection of bone metastases in prostate cancer and has been endorsed by recent oncology/urology guidelines. It is a sensitive method with modest specificity. (18)F-fluoride positron emission tomography/computed tomography has shown improved sensitivity and specificity over bone scintigraphy, but because of methodological issues such as retrospective design and verification bias, the existing level of evidence with (18)F-fluoride positron emission tomography/computed tomography is limited. The primary objective is to compare the diagnostic properties of (18)F-fluoride positron emission tomography/computed tomography versus bone scintigraphy on an individual patient basis.
One hundred forty consecutive, high-risk prostate cancer patients will be recruited from several hospitals in Denmark. Sample size was calculated using Hayen's method for diagnostic comparative studies. This study will be conducted in accordance with recommendations of standards for reporting diagnostic accuracy studies. Eligibility criteria comprise the following: 1) biopsy-proven prostate cancer, 2) PSA = 50 ng/ml (equals a prevalence of bone metastasis of ˜ 50% in the study population on bone scintigraphy), 3) patients must be eligible for androgen deprivation therapy, 4) no current or prior cancer (within the past 5 years), 5) ability to comply with imaging procedures, and 6) patients must not receive any investigational drugs. Planar bone scintigraphy and (18)F-fluoride positron emission tomography/computed tomography will be performed within a window of 14 days at baseline. All scans will be repeated after 26 weeks of androgen deprivation therapy, and response of individual lesions will be used for diagnostic classification of the lesions on baseline imaging among responding patients. A response is defined as PSA normalisation or = 80% reduction compared with baseline levels, testosterone below castration levels, no skeletal related events, and no clinical signs of progression. Images are read by blinded nuclear medicine physicians. The protocol is currently recruiting.
To the best of our knowledge, this is one of the largest prospective studies comparing (18)F-fluoride positron emission tomography/computed tomography and bone scintigraphy. It is conducted in full accordance with recommendations for diagnostic accuracy trials. It is intended to provide valid documentation for the use of (18)F-fluoride positron emission tomography/computed tomography for examination of bone metastasis in the staging of prostate cancer.
Notes
Cites: Eur Urol. 2014 Feb;65(2):467-7924321502
Cites: Eur J Cancer. 2014 Oct;50(15):2519-3125139492
Cites: Nat Rev Cancer. 2005 Jan;5(1):21-815630412
Cites: Semin Nucl Med. 2001 Jan;31(1):28-4911200203
Cites: Cancer. 2003 Feb 1;97(3 Suppl):758-7112548573
Cites: Fam Pract. 2004 Feb;21(1):4-1014760036
Cites: Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):BP99-10614989222
Cites: Clin Invest Med. 1982;5(4):267-756819101
Cites: AJR Am J Roentgenol. 1984 Apr;142(4):773-66230903
Cites: J Steroid Biochem. 1985 Nov;23(5B):833-412934579
Cites: Clin Nucl Med. 1990 Jul;15(7):485-72116949
Cites: J Nucl Med. 2006 Feb;47(2):287-9716455635
Cites: BMJ. 2008 May 17;336(7653):1106-1018483053
Cites: Lancet. 2008 May 17;371(9625):1710-2118486743
Cites: BJU Int. 2008 Dec;102(11):1531-819035858
Cites: Allergy. 2009 Aug;64(8):1109-1619489757
Cites: Br J Cancer. 2009 Oct 20;101(8):1225-3219789531
Cites: J Natl Compr Canc Netw. 2010 Feb;8(2):14520141674
Cites: J Urol. 2010 Jul;184(1):162-720483155
Cites: J Clin Epidemiol. 2010 Aug;63(8):883-9120079607
Cites: Nuklearmedizin. 2010;49(5):195-20120838734
Cites: J Nucl Med. 2010 Nov;51(11):1813-2021051652
Cites: J Clin Oncol. 2011 Jan 10;29(2):186-9121149653
Cites: Nucl Med Commun. 2011 Mar;32(3):168-7621076343
Cites: Eur Urol. 2011 Jan;59(1):61-7121056534
Cites: Nucl Med Commun. 2012 Apr;33(4):384-9422367858
Cites: Mol Imaging Biol. 2012 Apr;14(2):252-921479710
Cites: BMJ. 2012;345:e671723097549
Cites: J Nucl Med. 2013 Apr;54(4):590-923482667
Cites: Jpn J Radiol. 2013 Apr;31(4):262-923377765
Cites: Nucl Med Commun. 2013 Oct;34(10):935-4523903557
Cites: Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):59-6723974666
Cites: Clin Nucl Med. 2014 Jan;39(1):26-3124217537
Cites: Urol Oncol. 2014 Jan;32(1):38.e17-2823769268
Cites: BMJ. 2014;348:f752424401467
PubMed ID
26753880 View in PubMed
Less detail

(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

https://arctichealth.org/en/permalink/ahliterature272653
Source
Leuk Lymphoma. 2015 Jul;56(7):2005-12
Publication Type
Article
Date
Jul-2015
Author
Karen Juul Mylam
Lale Kostakoglu
Martin Hutchings
Morton Coleman
Dominick Lamonica
Myron S Czuczman
Louis F Diehl
Anne L Nielsen
Paw Jensen
Annika Loft
Helle W Hendel
Victor Iyer
Sirpa Leppä
Sirkku Jyrkkiö
Harald Holte
Mikael Eriksson
Dorte Gillstrøm
Per B Hansen
Marko Seppänen
Karin Hjorthaug
Peter de Nully Brown
Lars M Pedersen
Source
Leuk Lymphoma. 2015 Jul;56(7):2005-12
Date
Jul-2015
Language
English
Publication Type
Article
Keywords
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Denmark
Female
Finland
Fluorodeoxyglucose F18 - pharmacokinetics
Follow-Up Studies
Humans
Lymphoma, Large B-Cell, Diffuse - drug therapy - mortality - pathology
Male
Middle Aged
Multimodal Imaging
Neoplasm Staging
Norway
Positron-Emission Tomography - methods
Prognosis
Prospective Studies
Radiopharmaceuticals - pharmacokinetics
Survival Rate
Sweden
Tissue Distribution
Tomography, X-Ray Computed - methods
United States
Young Adult
Abstract
We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1-3 considered negative (D 5PS > 3) and D 5PS with scores 1-4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS > 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.
PubMed ID
25330442 View in PubMed
Less detail

18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.

https://arctichealth.org/en/permalink/ahliterature153281
Source
J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7
Publication Type
Article
Date
Oct-2008
Author
Max Dahele
Yee C Ung
Lisa Ehrlich
Jay Silverberg
Judith Balogh
C Shun Wong
Author Affiliation
Departmentof Radiation Oncology, University of Toronto, Edmond Odette Cancer Centre,Toronto, Ontario.
Source
J Otolaryngol Head Neck Surg. 2008 Oct;37(5):712-7
Date
Oct-2008
Language
English
Publication Type
Article
Keywords
Adult
Aged
Biological Markers - blood
Cancer Care Facilities
Carcinoma, Papillary - pathology - radionuclide imaging - surgery
Cohort Studies
Female
Fluorodeoxyglucose F18 - diagnostic use
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Recurrence, Local - pathology - radionuclide imaging - surgery
Neoplasm Staging
Ontario
Positron-Emission Tomography - methods
Reproducibility of Results
Retrospective Studies
Risk assessment
Sensitivity and specificity
Thyroglobulin - blood
Thyroid Neoplasms - pathology - radionuclide imaging - surgery
Thyroidectomy - methods
Time Factors
Treatment Outcome
Young Adult
Abstract
To report the initial experience with combined 18F-fluorodeoxyglucose positron emission tomography (FDG PET)/computed tomography (CT) imaging for suspected recurrent papillary differentiated thyroid cancer (DTC) at Sunnybrook Health Sciences Centre (SHSC), Toronto.
Single institution retrospective study.
Consecutive patients from SHSC who underwent FDG PET/CT imaging for suspected recurrent DTC over a period of 2.5 years were identified and their charts reviewed.
Qualitative appraisal of FDG PET/CT imaging in suspected recurrent DTC.
Sixteen patients (14F, 2M) were identified accounting for 17 FDG PET/CT scans. Three scans (18%) in 3 different patients were reported as suspicious for recurrent disease in the neck (1-3 lesions) and were considered "positive". All were subsequently confirmed pathologically (4-13 positive lymph nodes post operatively). Prior conventional imaging was abnormal in two patients. Two patients had an elevated non-stimulated thyroglobulin (TG)
PubMed ID
19128681 View in PubMed
Less detail

The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction.

https://arctichealth.org/en/permalink/ahliterature260854
Source
Endocr Pathol. 2014 Jun;25(2):186-92
Publication Type
Article
Date
Jun-2014
Author
G. Rindi
G. Petrone
F. Inzani
Source
Endocr Pathol. 2014 Jun;25(2):186-92
Date
Jun-2014
Language
English
Publication Type
Article
Keywords
Digestive System Neoplasms - classification
Humans
Neoplasm Grading - standards
Neoplasm Staging - standards
Neuroendocrine Tumors - classification
World Health Organization
Abstract
This paper briefly illustrates the basis, rules of application, and present outcome of the current World Health Organization (WHO) classification for neuroendocrine neoplasms. Established in 2010 upon the proposal from the European Neuroendocrine Tumor Society (ENETS), the WHO 2010 fostered some definitional changes (most notably the use of neuroendocrine tumor (NET) instead of carcinoid) and indicated the tools of grading and staging. Specific rules for its application were also defined. The data generated from the use of WHO 2010 classification substantially endorsed its rules and prognostic efficacy. In addition, the application demonstrated some issues, among which are the possible re-definition of the cutoff for grading G1 vs G2, as well as the possible identification of cases with somewhat different clinical behavior within the G3 neuroendocrine cancer class. Overall, since the recent introduction of WHO 2010 grading and staging, it appears wise to keep the current descriptors to avoid unnecessary confusion and to generate comparable data. Homogenous data on large series are ultimately needed to solve such issues.
PubMed ID
24699927 View in PubMed
Less detail

2021 records – page 1 of 203.